Sofpironium (Sofdra) for Primary Axillary Hyperhidrosis
Sofpironium (Sofdra) for Primary Axillary Hyperhidrosis
August 19, 2024 (Issue: 1709)
The FDA has approved a 12.45% gel formulation of the
anticholinergic drug sofpironium (Sofdra – Botanix) for
treatment of primary axillary hyperhidrosis (excessive
underarm sweating) in patients ≥9 years old.
- Qbrexza – a glycopyrronium cloth for axillary hyperhidrosis. Med Lett Drugs Ther 2019; 61:10.
- DA Glaser et al. Outcomes from the SAHARA clinical study on the TAT patch for excessive axillary sweating or primary axillary hyperhidrosis. Music City SCALE Meeting; Nashville, TN; May 17-21, 2023. Available at: https://bit.ly/3LfMcyB. Accessed August 1, 2024.
- SL Gray et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med 2015; 175:401. doi:10.1001/jamainternmed.2014.7663
- S Nawrocki and J Cha. Botulinum toxin: pharmacology and injectable administration for the treatment of primary hyperhidrosis. J Am Acad Dermatol 2020; 82:969. doi:10.1016/j.jaad.2019.11.042
- DH Kim et al. Treatment of palmar hyperhidrosis with tap water iontophoresis: a randomized, sham-controlled, single-blind, and parallel-designed clinical trial. Ann Dermatol 2017; 29:728. doi:10.5021/ad.2017.29.6.728
- S Nawrocki and J Cha. The etiology, diagnosis, and management of hyperhidrosis: a comprehensive review: therapeutic options. J Am Acad Dermatol 2019; 81:669. doi:10.1016/j.jaad.2018.11.066
- Inhibitors and inducers of CYP enzymes, P-glycoprotein, and other transporters. Med Lett Drugs Ther 2023 January 25 (epub). Available at: www.medicalletter.org/downloads/CYP_PGP_Tables.pdf.
- Approximate WAC. WAC = wholesaler acquisition cost or manufacturer’s published price to wholesalers; WAC represents a published catalogue or list price and may not represent an actual transactional price. Source: AnalySource® Monthly. July 5, 2024. Reprinted with permission by First Databank, Inc. All rights reserved. ©2024. www.fdbhealth.com/drug-pricing-policy.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to
The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Purchase this article:
Title: Sofpironium (Sofdra) for Primary Axillary Hyperhidrosis
Article code: 1709c
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
